Note
Remarkable increase of Neisseria gonorrhoeae with decreased susceptibility of azithromycin and increase in the failure of azithromycin therapy in male gonococcal urethritis in Sendai in 2015

https://doi.org/10.1016/j.jiac.2016.07.012Get rights and content

Abstract

The antimicrobial resistance of Neisseria gonorrhoeae is a serious problem worldwide. In this study, we examined the susceptibility of N. gonorrhoeae isolated from male gonococcal urethritis in Sendai in 2014 and 2015. Furthermore, of all cases, we investigated the clinical efficacy of a single 2-g dose of extended-release azithromycin (AZM-SR) in the treatment of male gonococcal urethritis retrospectively. Sixty N. gonorrhoeae strains in 2014 and 54 strains in 2015 were isolated from male gonococcal urethritis and stored each year. The MIC of AZM was ≥1 mg/L in 4 strains (6.7%) in 2014 and in 13 strains (24.1%) in 2015 and the number of strains having ≥1 mg/L MIC increased significantly (P = 0.016). Microbiological efficacy was evaluated in 32 and 29 of these patients, and the rates of treatment success were 93.8% and 79.3%, respectively. All of the treatment failures were caused by strains having a MIC of AZM of ≥0.5 mg/L. In particular, the increase in the isolates having a MIC of AZM of ≥1 mg/L was remarkable. Therefore, it was thought that the increase in these strains was the reason for the increase in treatment failures in 2015. Because no other drug is effective, it is currently necessary to use AZM-SR to treat gonococcal infections caused by ceftriaxone-resistant strains or patients allergic to ceftriaxone. To prevent a further increase in resistance to AZM, we should not use AZM-SR to treat normal cases of gonococcal infection.

Section snippets

Conflict of interest

This work was supported in part by the Japan Society for the Promotion of Science (JSPS), Japan (Grant-in-Aid for Scientific Research [C] 25462509 and [C] 26462442) and by the Research Program on Emerging and Re-emerging Infectious Diseases, Japan Agency for Medical Research and Development (15fk0108014h0001).

Acknowledgements

We thank the patients of iClinic, Sendai, Japan.

References (15)

There are more references available in the full text version of this article.

Cited by (21)

  • The JAID/JSC guidelines to Clinical Management of Infectious Disease 2017 concerning male urethritis and related disorders

    2021, Journal of Infection and Chemotherapy
    Citation Excerpt :

    While the spread of CTRX-resistant strains has not been observed, increases in CTRX low-sensitivity strains have been reported from various parts of the world [57,83], and their trends are attracting attention (IV, B). Although AZM is recognized to be effective against gonococcal infection, there have been a number of reports of regional surveillance data indicating decreases in responses to this drug [84]. Moreover, as there have been a series of reports of N. gonorrhoeae strains highly resistant to AZM from foreign countries, AZM is not recommended as the first-line drug in the Japanese guidelines [67–71] (II, B).

  • Urethritis

    2020, FMC Formacion Medica Continuada en Atencion Primaria
  • Management of Urethritis: Is It Still the Time for Empirical Antibiotic Treatments?

    2019, European Urology Focus
    Citation Excerpt :

    Owing to the widespread high levels of cephalosporin resistance, first-line treatment consists of combined therapy using a single dose of ceftriaxone 250 mg (1 g IM) plus azithromycin 1 g (2 g orally), although the European Association of Urology guideline recommendation indicated the need to administer at least ceftriaxone 1 g in combination with azithromycin 1 g to avoid the risk of undertreatment (LE 2a) [2,14,21,26,27]. Azithromycin is preferred to doxycycline because of the convenience and compliance advantages of single-dose therapy and the substantially higher prevalence of gonococcal resistance to tetracycline than to azithromycin (LE 2a) [28,29]. Therefore, this dual therapy will not entirely prevent the emerging resistance.

  • Sustained transmission of high-level azithromycin-resistant Neisseria gonorrhoeae in England: an observational study

    2018, The Lancet Infectious Diseases
    Citation Excerpt :

    Even low-level azithromycin resistance is likely to render the azithromycin component of dual therapy ineffective. In a Japanese study,27 treatment failures in men with gonococcal urethritis treated with an extended-release 2 g azithromycin single dose were associated with azithromycin MICs of higher than 0·5 mg/L. Additionally, the in-vitro MIC of azithromycin does not necessarily correlate with clinical treatment outcome, and treatment failures occur in patients with isolates identified as azithromycin susceptible in the laboratory.28 In conclusion, sustained transmission of a successful HL-AziR N gonorrhoeae clone has been observed across England.

  • Health risks and precautions for visitors to the Tokyo 2020 Olympic and Paralympic Games

    2018, Travel Medicine and Infectious Disease
    Citation Excerpt :

    Among the cases in 2016, 37% (1673 cases) were reported from Tokyo [52]. In addition, there are increasing numbers of drug-resistant gonorrhea cases globally, including in Japan [53–55]. The total number of non-drug resistant gonorrhea cases in Japan was 8298 in 2016, decreasing from 8698 in 2015 [51]; however, this disease could spread both within and outside Japan, which may result in epidemics across different countries.

View all citing articles on Scopus
View full text